Aerosol polymyxin and pneumonia in seriously ill patients.
Pneumonia caused by Pseudomonas aeruginosa occurs frequently in critically ill patients and is associated with a mortality rate of 70 per cent. An aerosol of polymyxin B was administered (2.5 mg per kilogram per day) to the upper airways of 292 patients in a respiratory-surgical intensive-care unit during a seven-month period, in an attempt to prevent Ps. aeruginosa pneumonia. Although only one of the patients studied acquired pneumonia due to Ps. aeruginosa, 10 others acquired pneumonia caused by a polymysinx-resistant organism. Seven pneumonias were caused by organisms not frequently pathogenic to man (flavobacteria, serratia and Streptococcus faecalis). The mortality rate for acquired pneumonia in this study, 64 per cent, is greater than that in previous studies in which either no polymyxin or cyclic polymyxin therapy was used. Continuous use of polymyxin B aerosol appears to be a dangerous form of therapy.
D000336:Aerosols; D001419:Bacteria / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D006801:Humans; D007362:Intensive Care Units; D011014:Pneumonia / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control*; D011113:Polymyxins / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D011183:Postoperative Complications / Q000517:prevention & control; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013997:Time Factors
D000336:Aerosols; D011113:Polymyxins